paediatric low-grade gliomas
Ipsen’s cabozantinib accepted by SMC for adults with advanced neuroendocrine tumours
NETs affect approximately seven per 100,000 people in Scotland
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
Key takeaways from ASCO® 2026
Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...
Ipsen to acquire Memo Therapeutics in deal worth more than €700m
The deal expands the company’s rare disease portfolio
Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
Pfizer and Innovent Biologics agree on deal worth up to $10.5bn
The companies plan to research and develop 12 new cancer treatments
One-carbon Therapeutics collaborates with Tempus in cancer treatment
The treatment is currently being evaluated in a phase 1/2 multicentre clinical study
Gilead to acquire Tubulis for up to $5bn
The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need
Ipsen appoints Michelle Werner as Executive Vice President, President of North America
Werner previously held senior roles at Bristol Myers Squibb, AstraZeneca and Novartis
Ipsen appoints Pierrick Lefranc as Executive Vice President Technical Operations
Lefranc has served at Ipsen since 2013, most recently as Senior Vice President
Vibrant Therapeutics raises $61m in funding to advance intelligent therapeutics pipeline
The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m
AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer
Around one in five breast cancer cases are HER2-positive